Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

23-09-2016(Fri) 22-09-2016(Thu) 21-09-2016(Wed) 20-09-2016(Tue) 19-09-2016(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
23 Sep, 2016 (Friday)

            
PLOVER BAY TECH(1523)
Analysis¡G
Plover Bay Technologies (1523) is principally engaged in the design, development, marketing and sale of SD-WAN router. Its products and services are used by enterprise users as well as industry users to resolve their WAN connection issues. For the six months ended 30 June 2016, its revenue amounted to US$12.03 million, representing an increase of 12.1% as compared to the same period last year. Profit attributable to shareholders was US$2.8 million, representing an increase of 102.2%.Gross profit margin was 55.4%, representing an increase of 10.4 percentage points. The SD-WAN router market is projected to grow at a compound annual growth rate of 31.8% from 2015 to reach US$1.51 billion by 2020. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $0.46, Target Price: $0.52, Cut Loss Price: $0.43

YiBai Pharmaceutical(600594)
Analysis¡G
Yibai Pharmaceutical achieved 188% growth of net profit in 1H16. We hold that the launch of second-tier products and normalizing expenses ratio will fuel the company's ongoing growth. Meanwhile, by virtue of abundant cash reserves and well-performing cash flow of the pharmacy business, the company is expected to keep promoting multi-model acquisition and expansion of medical services, develop a tumor treatment system that integrates surgery, radiotherapy, chemotherapy, imaging, diagnosis, rehabilitation and precision medicine, and build a close-loop ecosystem of the tumor industry featuring "medicine + hospital + doctor". The model of medical group involves doctors in management and investment. It is also expected to address the issues of private capitals investing in hospitals. We believe the model embraces promising prospects.
Strategy¡G
Buy-in Price: $16.57, Target Price: $18.00, Cut Loss Price: $16.00


CAR Inc (699.HK) - Better Free Cash Flow

Interim Net Profit Soared by 161%

CAR announced the interim results as of June 30, 2016. Its net profit amounted to RMB 1.062 billion (same below), representing a YoY soar of 160.73%. EPS was RMB 0.444, as compared with RMB 0.172 in 2015H. No interim dividends. During the reporting period, turnover stood at RMB 2.969 billion, increasing by 28.67% year on year. Gross profit was RMB 1.103 billion, up 13.27% over the previous year, while the gross profit margin dropped from 49.1% to 45%, which mainly results from the increase in depreciation and increase in the costs of the new business of B2C second-hand vehicles.

Significant reasons for soar in profit are as follows: The fair value gains derived from the equities in UCAR Technology (China) Limited stood at RMB 827 million, and the unrealized foreign exchange losses of some dollar-denominated liabilities amounted to RMB 116 million. If such impact is excluded, the actual net profit increased by around 12% as compared with the same period last year.

Growth in the Fleet Size Continued to Decrease

In the early stage, the Company has decided to make adjustment in its development strategies, slow down the pace of expansion and change from extensive growth to giving priority to efficiency. As of the end of June, the Company's total fleet size reached 99,727 units, rising by 17.7% over last year, and growing by 9.4% as compared with the end of 2015. The fleet size stood at 87,585 units, increasing by 8.6% over the previous year but only by 5.3% as compared with the end of 2015. The Company's capital expenditure in H1 2016 amounted to RMB 1.26 billion, representing a YoY plunge of 70% but a MoM increase of 19.5%. In the second quarter, the Company sped up the phase-out of old models and the upgrade of new models in order to enhance the customer experience, while actively promoting free car delivery services to consolidate its competitive edge.

Cooperated with UCAR Inc. to Boost the Fleet's Operational Efficiency

The Company's short-term rental income surged by 16% over 2015 to RMB 1.7 billion, which is basically consistent with the increase of the total fleet. Besides, its long-term rental income skyrocketed by 57% over the previous year to RMB 722 million, which is primarily attributable to the growth in the fleet of UCAR Inc. Approximately 10,000 long-term rental vehicles and 20,000 short-term rental vehicles of the Company were rented to UCAR Inc. By means of cooperating with UCAR Inc., the Company optimized the management of dynamic fleet sharing in low and high seasons, boosted the utilization efficiency of the fleet which moderately increased by 0.2 percentage points to 64.1% and offset some negative impact of a 2.5% drop in the average daily rent.

Free Cash Flow Turned from Outflow to Inflow

Benefiting from the decline in capital expenditure on rental vehicles and the rise in cash flow from operation, the Company's free cash flow improved from last year's outflow of RMB 3.76 billion to this year's inflow of RMB 784 million.

Formal Promulgation of New Ride-hailing Policy Contributed to Indirect Benefits

At the end of July, the government formally promulgated the new ride-hailing policy. We believe that this policy produces more significant adverse effect on major competitors of UCAR Inc. and will prevent the C2C platform's exorbitant expensive, thereby lowering the price pressure faced by UCAR Inc. and indirectly benefiting the long-term development of the Company's future business.

Investment Thesis

We adjusted the earnings per share to RMB0.69/0.57 in 2016/2017. The company's current valuation has relatively great safety margin, and we still believe that the innovation and strong power of execution of the company will enable us to face future challenges. We give a target price of HKD9.61, equivalent to the 12/14.7 x P/E ratio in 2016/2017. The accumulate rating was reaffirmed. (Closing price as at 19 Sep 2016)

Financials

Click Here for PDF format...




Recommendation on 23-9-2016
RecommendationAccumulate
Price on Recommendation Date$ 8.280
Suggested purchase priceN/A
Target Price$ 9.610
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+ 86 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre


Stock Borrowing & Lending



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong ½÷¥ß¬ã¨s³¡ ¡V ­»´ä¤Î¤¤°ê
Company Stock Code Last Update Suggestion Target Price Price on Recom
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
CAR Inc69923/09/2016Accumulate9.610.000
Yutong60006615/09/2016Buy2722.07
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
China Traditional Chinese Medicine57013/09/2016Accumulate4.43.98
China Traditional Chinese Medicine57012/09/2016Accumulate4.43.98
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Essex Bio-Technology106122/09/2016Buy4.523.62
Essex Bio-Technology106121/09/2016Buy4.523.62
New Energy Research Department (86) 21 51699400-110research@phillip.com.cn
Yunnan Water683923/05/2016Buy5.73.94
Grandblue ENV60032320/04/2016Buy 17.513.11
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
361 Degrees136126/08/2016Buy3.22.48
Poly Culture363625/08/2016Accumulate23.519.84
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
Byaa Interactive43405/07/2016Accumulate32.71
Kingsoft Corporation Limited388828/06/2016Buy19.114.86
Mainland Property Research Department (86) 21 51699400-110research@phillip.com.cn
¤Ñ¼w¤Æ¤u60906/09/2016¼ÈµLµû¯Å1.95
Fortune REIT77823/08/2016No Rating9.65
Utilities Research Department (86) 21 51699400-110research@phillip.com.cn
Beijing Enterprises Water Group Limited37120/09/2016BUY7.25.46
Beijing Enterprises Water Group Limited37119/09/2016BUY7.25.46
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
Goldpac Group331518/02/2015N/A4.77
IGG800221/11/2014Accumulate3.953.44
Hotels and Entertainment Zhang Jing (+ 86 51699400-103)zhangjing@phillip.com.cn
Jinjiang Hotels200608/07/2016Accumulate2.982.49
CUTC60035808/03/2016N/A10.41

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2016 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]